Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Denali Therapeutics (DNLI) Receivables - Other (2017 - 2022)

Denali Therapeutics (DNLI) has disclosed Receivables - Other for 5 consecutive years, with $357000.0 as the latest value for Q2 2022.

  • Quarterly Receivables - Other fell 77.22% to $357000.0 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $357000.0 through Jun 2022, down 77.22% year-over-year, with the annual reading at $1.2 million for FY2021, 78.39% down from the prior year.
  • Receivables - Other for Q2 2022 was $357000.0 at Denali Therapeutics, down from $1.2 million in the prior quarter.
  • The five-year high for Receivables - Other was $5.7 million in Q4 2020, with the low at $357000.0 in Q2 2022.
  • Average Receivables - Other over 4 years is $2.0 million, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Receivables - Other surged 154.74% in 2018, then plummeted 78.39% in 2021.
  • Over 4 years, Receivables - Other stood at $1.2 million in 2018, then soared by 380.03% to $5.7 million in 2020, then tumbled by 78.39% to $1.2 million in 2021, then tumbled by 70.88% to $357000.0 in 2022.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $357000.0, $1.2 million, and $1.2 million for Q2 2022, Q4 2021, and Q3 2021 respectively.